<DOC>
	<DOCNO>NCT01579461</DOCNO>
	<brief_summary>The study aim investigate compare effect Mirabegron ( YM178 ) subject mild moderate hepatic impairment compare healthy subject .</brief_summary>
	<brief_title>A Study Investigate Effect Mirabegron ( YM178 ) Subjects With Mild Moderate Hepatic Impairment Compared Healthy Subjects</brief_title>
	<detailed_description>Healthy subject subject mild moderate hepatic impairment admit Day 1 . Subjects receive single oral dose Mirabegron morning Day 1 remain unit till Day 5 outpatient visit Days 6 7 healthy subject Days 6 , 7 , 9 11 subject hepatic impairment . Blood sample PK assessment 144 hr post dose healthy subject 240 hr post dose subject hepatic impairment . An additional blood sample obtain subject 4 hr post dose protein binding .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body Mass Index equal 18.0 less 32.0 kg/m2 ( men woman ) Subject genotyped extensive metabolizer CYP2D6 For subject mild/moderate hepatic impairment : Hepatic dysfunction score mild impairment ( ( 56 ChildPugh 's classification ) moderate impairment ( 79 ChildPugh 's classification ) Healthy subject normal hepatic function Known suspect hypersensitivity mirabegron component formulation use A marked prolongation screen QT/QTC interval demonstrate mean QTcF interval &gt; 450 m male subject mean QTcF interval &gt; 470 m female subject ( base 3 ECGs ) Abnormal pulse rate and/or blood pressure measurement prestudy visit take triplicate mean automatic device , subject rest supine position 5 min : â€¢Pulse rate &lt; 40 &gt; 90 bpm ; Mean systolic blood pressure &lt; 90 &gt; 160 mmHg ; Mean diastolic blood pressure &lt; 40 &gt; 95 mmHg Healthy subject : use prescribe OTC drug ( except paracetamol , maximum 3g/day ) 2 week prior admission clinical unit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>mirabegron</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>Phase 1</keyword>
</DOC>